Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

78.17 +0.62 (+0.81%)
Streaming Delayed Price Updated: 1:33 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,333,759
Open 78.17
Bid (Size) 78.16 (3)
Ask (Size) 78.17 (1)
Prev. Close 77.54
Today's Range 77.80 - 78.78
52wk Range 60.47 - 87.67
Shares Outstanding N/A
Dividend Yield 1.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, showcasing significant improvements in progression-free survival rates. 
Via Benzinga
Exposures Product Safety
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
+14.28%
+14.28%
1 Month
-9.76%
-9.76%
3 Month
-1.16%
-1.16%
6 Month
+14.51%
+14.51%
1 Year
+14.58%
+14.58%

More News

Read More
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Via Benzinga
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
Via Investor's Business Daily
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
Via Benzinga
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
From AstraZeneca
Via Business Wire
FLUMIST approved for self-administration in the US
From AstraZeneca
Via Business Wire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Via The Motley Fool
Topics Stocks
Exposures US Equities
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
Via Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
Via Benzinga
Exposures Product Safety
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
From AstraZeneca
Via Business Wire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
5 Oversold Stocks to Buy Right Now
Via MarketBeat
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
From AstraZeneca
Via Business Wire
Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push
Via Investor's Business Daily
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
Via Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.